A phase IIIb/IV randomized, controlled, open label, parallel group study to compare the efficacy of vancomycin therapy to extended duration fidaxomicin therapy in the sustained clinical cure of Clostridium difficile Infection in an older population

Trial Profile

A phase IIIb/IV randomized, controlled, open label, parallel group study to compare the efficacy of vancomycin therapy to extended duration fidaxomicin therapy in the sustained clinical cure of Clostridium difficile Infection in an older population

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Fidaxomicin (Primary) ; Vancomycin
  • Indications Clostridium infections
  • Focus Therapeutic Use
  • Acronyms EXTEND
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 08 Oct 2017 Results of subgroup analysis assessing impact of baseline factors presented at the IDWeek 2017
    • 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 23 Apr 2017 Primary endpoint (The primary endpoint of this study is sustained clinical cure of CDI) has been met, according to a Astellas Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top